NTHI
Neonc Technologies Holdings, Inc.
$3.45
+0.12
(+3.60%)
Mkt Cap
89.46M
Volume
146,201
52W Range
2.955-12.99
Sector
Healthcare
Beta
0.50
EPS (TTM)
-2.22 USD
P/E Ratio
-2.56
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 |
|---|---|
| Revenue | 39,990 |
| Net Income | (62.15M) |
| EPS | -3.23 |
| Free Cash Flow | (20.86M) |
| FCF / Share | -1.09 |
| Operating CF | (20.36M) |
| Total Assets | 2.82M |
| Total Debt | 6.31M |
| Cash & Equiv | 58,729 |
| Book Value | (17.51M) |
| Return on Equity | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 39,990 |
| Net Income | (14.24M) | (8.82M) | (15.52M) | (8.62M) | (5.68M) | (38.00M) |
| EPS | -0.58 | -0.38 | -0.81 | -0.45 | -0.30 | -2.10 |
| Free Cash Flow | (4.77M) | (6.99M) | (3.59M) | (5.81M) | (5.31M) | (5.65M) |
| FCF / Share | -0.19 | -0.30 | -0.19 | -0.30 | -0.28 | -0.31 |
| Operating CF | (4.77M) | (6.99M) | (3.59M) | (5.81M) | (5.31M) | (5.65M) |
| Total Assets | 5.23M | 3.33M | 2.82M | 4.08M | 2.99M | 8.44M |
| Total Debt | 328,217 | 346,053 | 6.31M | 378,741 | 395,512 | 0 |
| Cash & Equiv | 1.97M | 138,601 | 58,729 | 1.51M | 125,039 | 5.44M |
| Book Value | (18.53M) | (13.23M) | (17.51M) | (11.81M) | (11.82M) | (9.62M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
NTHI News
NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier
NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors